These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
505 related articles for article (PubMed ID: 30105948)
1. Intermediate-Risk Papillary Thyroid Cancer: Risk Factors for Early Recurrence in Patients with Excellent Response to Initial Therapy. Llamas-Olier AE; Cuéllar DI; Buitrago G Thyroid; 2018 Oct; 28(10):1311-1317. PubMed ID: 30105948 [TBL] [Abstract][Full Text] [Related]
2. Predictors of response to Radioactive Iodine Therapy in Intermediate and high risk patients with papillary thyroid carcinoma. Keshavarzi A; Alaei-Shahmiri F; Fallahi B; Emami Z; Malek M; Khamseh ME BMC Endocr Disord; 2024 Jul; 24(1):112. PubMed ID: 39004697 [TBL] [Abstract][Full Text] [Related]
3. Is surgical resection without radioactive iodine treatment a safe alternative treatment for T1-2N1bM0 papillary thyroid carcinoma? Fujiwara T; Yoshizawa A; Mizuta M; Tamaki H Auris Nasus Larynx; 2021 Feb; 48(1):148-153. PubMed ID: 32718811 [TBL] [Abstract][Full Text] [Related]
4. Predictors of recurrence after total thyroidectomy plus neck dissection and radioactive iodine ablation for high-risk papillary thyroid carcinoma. Kim Y; Roh JL; Song D; Cho KJ; Choi SH; Nam SY; Kim SY J Surg Oncol; 2020 Oct; 122(5):906-913. PubMed ID: 32588461 [TBL] [Abstract][Full Text] [Related]
5. Thyroid ablation with 1.1 GBq (30 mCi) iodine-131 in patients with papillary thyroid carcinoma at intermediate risk for recurrence. Rosário PW; Calsolari MR Thyroid; 2014 May; 24(5):826-31. PubMed ID: 24283207 [TBL] [Abstract][Full Text] [Related]
6. Microscopic positive margins in papillary thyroid cancer do not impact disease recurrence. Abraham E; Tran B; Roshan D; Graham S; Lehane C; Wykes J; Campbell P; Ebrahimi A ANZ J Surg; 2018 Nov; 88(11):1193-1197. PubMed ID: 29701284 [TBL] [Abstract][Full Text] [Related]
7. RAI therapy in low-risk papillary thyroid cancer: recurrence reduction and long-term outcomes in the Turkish population. Bilgic S; Meral R; Sağer MS; Sönmezoğlu K BMC Cancer; 2024 Oct; 24(1):1273. PubMed ID: 39402494 [TBL] [Abstract][Full Text] [Related]
8. Higher administered activities of radioactive iodine are associated with less structural persistent response in older, but not younger, papillary thyroid cancer patients with lateral neck lymph node metastases. Sabra MM; Grewal RK; Ghossein RA; Tuttle RM Thyroid; 2014 Jul; 24(7):1088-95. PubMed ID: 24559250 [TBL] [Abstract][Full Text] [Related]
9. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy? Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181 [TBL] [Abstract][Full Text] [Related]
10. Impact factors for the outcome of the first Shangguan L; Fang S; Zhang P; Han S; Shen X; Geng Y; Luo D; Zhao C Ann Nucl Med; 2019 Mar; 33(3):177-183. PubMed ID: 30515649 [TBL] [Abstract][Full Text] [Related]
11. Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy. Vassilopoulou-Sellin R; Schultz PN; Haynie TP Cancer; 1996 Aug; 78(3):493-501. PubMed ID: 8697396 [TBL] [Abstract][Full Text] [Related]
12. Clinical response to radioactive iodine therapy for prophylactic central neck dissection is not superior to total thyroidectomy alone in cN0 patients with papillary thyroid cancer. Lin B; Qiang W; Wenqi Z; Tianyu Y; Lina Z; Bin J Nucl Med Commun; 2017 Dec; 38(12):1036-1040. PubMed ID: 28953211 [TBL] [Abstract][Full Text] [Related]
13. Radioactive iodine ablation does not prevent recurrences in patients with papillary thyroid microcarcinoma. Kim HJ; Kim NK; Choi JH; Kim SW; Jin SM; Suh S; Bae JC; Min YK; Chung JH; Kim SW Clin Endocrinol (Oxf); 2013 Apr; 78(4):614-20. PubMed ID: 22957654 [TBL] [Abstract][Full Text] [Related]
14. Association of Radioactive Iodine Administration After Reoperation With Outcomes Among Patients With Recurrent or Persistent Papillary Thyroid Cancer. Hung ML; Wu JX; Li N; Livhits MJ; Yeh MW JAMA Surg; 2018 Dec; 153(12):1098-1104. PubMed ID: 30140908 [TBL] [Abstract][Full Text] [Related]
15. Analysis of delayed initial radioactive iodine therapy and clinical outcomes in papillary thyroid cancer: a two-center retrospective study. He T; Li M; Gao ZL; Li XY; Zhong HR; Ding CS; Cai HW Nucl Med Commun; 2024 Sep; 45(9):779-787. PubMed ID: 38832411 [TBL] [Abstract][Full Text] [Related]
16. Risk Factors for Recurrence After Treatment of N1b Papillary Thyroid Carcinoma. Lee SH; Roh JL; Gong G; Cho KJ; Choi SH; Nam SY; Kim SY Ann Surg; 2019 May; 269(5):966-971. PubMed ID: 29462007 [TBL] [Abstract][Full Text] [Related]
17. Clinical Outcomes of N1b Papillary Thyroid Cancer Patients Treated with Two Different Doses of Radioiodine Ablation Therapy. Jin M; Ahn J; Lee YM; Sung TY; Kim WG; Kim TY; Ryu JS; Kim WB; Shong YK; Jeon MJ Endocrinol Metab (Seoul); 2020 Sep; 35(3):602-609. PubMed ID: 32981302 [TBL] [Abstract][Full Text] [Related]
18. Utility of adjuvant radioactive iodine therapy after reoperation in papillary thyroid carcinoma with cervical lymph node recurrence. Zhang Y; Zhu X; Fan Q; Huang Q; Tu Y; Jiang L; Zhang Z; Chen J Jpn J Radiol; 2023 Oct; 41(10):1148-1156. PubMed ID: 37266825 [TBL] [Abstract][Full Text] [Related]
19. Is Postoperative Adjuvant Radioactive Iodine Ablation Therapy Always Necessary for Intermediate-Risk Papillary Thyroid Cancer Patients With Central Neck Metastasis? Han K; Noh HM; Jeong HM; Lim YC Ann Surg Oncol; 2021 Nov; 28(12):7533-7544. PubMed ID: 34043093 [TBL] [Abstract][Full Text] [Related]
20. Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma. Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS Endocr Relat Cancer; 2016 May; 23(5):367-76. PubMed ID: 26917553 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]